{"altmetric_id":23110904,"counts":{"readers":{"mendeley":4,"citeulike":0,"connotea":0},"total":{"posts_count":1},"policy":{"unique_users_count":1,"unique_users":["nber"],"posts_count":1}},"citation":{"altmetric_jid":"4f6fa4f03cf058f610002d05","authors":["Natalie R. Phelan","Drusilla Raiford","Betsy Morris","Phelan, Natalie R.","Raiford, Drusilla","Morris, Betsy"],"doi":"10.1002\/j.1552-4604.1991.tb01882.x","endpage":"24","first_seen_on":"2017-07-29T13:45:03+00:00","issns":["00912700","1552-4604"],"issue":"1","journal":"Journal of Clinical Pharmacology","last_mentioned_on":1170288000,"links":["http:\/\/dx.doi.org\/10.1002\/j.1552-4604.1991.tb01882.x"],"pdf_url":"http:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/j.1552-4604.1991.tb01882.x\/pdf","pubdate":"1991-01-01T00:00:00+00:00","publisher":"Blackwell Publishing Ltd","publisher_subjects":[{"name":"Pharmacology And Pharmaceutical Sciences","scheme":"era"}],"scopus_subjects":["Health Sciences","Medicine","Life Sciences","Pharmacology, Toxicology and Pharmaceutics"],"startpage":"17","title":"Therapeutic Ratings and End-of-Phase II Conferences: Initiatives to Accelerate the Availability of Important New Drugs Kenneth I. Kaitin, PhD","type":"article","volume":"31","mendeley_url":"http:\/\/www.mendeley.com\/research\/therapeutic-ratings-endofphase-ii-conferences-initiatives-accelerate-availability-important-new-drug"},"altmetric_score":{"score":3,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":3},"context_for_score":{"all":{"total_number_of_other_articles":8151797,"mean":6.8917892822572,"rank":2059893,"this_scored_higher_than_pct":60,"this_scored_higher_than":4964276,"rank_type":"exact","sample_size":8151797,"percentile":60},"similar_age_3m":{"total_number_of_other_articles":101405,"mean":10.746363752909,"rank":31231,"this_scored_higher_than_pct":68,"this_scored_higher_than":69115,"rank_type":"exact","sample_size":101405,"percentile":68},"this_journal":{"total_number_of_other_articles":899,"mean":4.7229599109131,"rank":178,"this_scored_higher_than_pct":49,"this_scored_higher_than":441,"rank_type":"exact","sample_size":899,"percentile":49},"similar_age_this_journal_3m":{"total_number_of_other_articles":8,"mean":12.885714285714,"rank":4,"this_scored_higher_than_pct":50,"this_scored_higher_than":4,"rank_type":"exact","sample_size":8,"percentile":50}}},"demographics":{"users":{"mendeley":{"by_status":{"Researcher":1,"Student  > Master":3},"by_discipline":{"Social Sciences":2,"Economics, Econometrics and Finance":1,"Environmental Science":1}}}},"posts":{"policy":[{"title":"Anti-depressants and Suicide","url":"http:\/\/www.nber.org\/papers\/w12906.pdf","license":"public","citation_ids":[8423084,15044221,3203064,2164632,15268312,23110466,8423083,23110852,23110857,123708,23110864,15439637,23110873,417861,23110897,8424462,1508680,2552909,2414012,1083966,242259,23110904,5887809,1368105,23110914,630497,9132416,2009319,23110919,23110925,14980922,23110933,23110956,1740253,23110957,2144028,8482991,3418107,16171404,2767096],"posted_on":"2007-02-01T00:00:00+00:00","source":{"name":"National Bureau of Economic Research","description":"The National Bureau of Economic Research (NBER) is a private, non-profit, non-partisan organisation dedicated to conducting economic research and to disseminating research findings among academics, public policy makers, and business professionals.","geo":{"country":"US"}},"page_url":"http:\/\/www.nber.org\/papers\/w12906","collections":[],"author":{"image":"https:\/\/s3.amazonaws.com\/cache.altmetric.com\/policy\/thumbnails\/thumbnail-9610ac92003f187f9382cb93d45f6725968f41bdbb99368cb77df700b27cfd28.jpg"}}]}}